CTLA4 and colitis: Of these, 173 (8.7%) who had developed immunotherapy-related colitis were matched with an equal number of control patients without colitis to receive immunotherapy with CTLA-4- or PD-1/PD-L1-targeted MAbs individually or in combination (60).